Summary of "Video clase Uso Racional de Analgesicos"

Key Wellness / Safety / Productivity Takeaways (from the Class)

This lecture focuses on rational, evidence-based pain control using analgesics, emphasizing safety, correct patient assessment, and avoiding medication misuse.

1) Start with a thorough pain assessment (don’t treat “pain” blindly)

Pain must be evaluated as multifactorial, not as a single number. Key dimensions to consider:

Context/temporality: acute vs. chronic
Location: peripheral/somatic vs. visceral
Mechanism/type:
- Nociceptive (e.g., trauma receptor activation)
- Neuropathic (nervous system impairment)
Intensity
Impact on quality of life

Treatment should be tailored to the patient in front of you, incorporating history, comorbidities, and risk factors.

2) Use standardized pain measurement tools (with awareness of subjectivity)

Pain is subjective, and scales are helpful but imperfect. The lecture highlighted:

Visual Analogue Scale (VAS): typically a 1 cm reference from “no pain” to “worst imaginable pain”

Clinicians should combine:

the patient’s report
the team’s observations
other clinical parameters

For pediatrics, choose tools appropriate to practicality and feasibility.

3) Apply the “analgesic ladder” / stepwise escalation (evidence-based protocols)

The lecture emphasizes institutional protocols and standardization. Escalation should match severity:

Step 1 (mild pain): e.g., paracetamol or NSAIDs
Step 2 (moderate pain): e.g., tramadol (a weaker opioid) and adjuvants
Step 3 (severe pain): potent opioids such as morphine
Step 4 (specialized care): palliative care / pain specialists

4) Understand “coadjuvants” for neuropathic pain (different approach than nociceptive pain)

Neuropathic pain generally requires adjuvant (coadjuvant) medicines, not just typical analgesics.

This differs from the classic analgesic ladder approach.
Examples mentioned:
- Antiepileptics + antidepressants as coadjuvants
Weak vs. potent opioids may also be combined depending on stage/need.

5) Be careful with medication combinations (synergy vs “stacking” risks)

Combination therapy can be beneficial, but the goal is:

Synergism: different mechanisms that provide added benefit
Avoid toxicity/adverse effects accumulating

Key warning: avoid combining two drugs with the same mechanism of action (example: two NSAIDs).

Example strategy: use step-based additions (e.g., NSAID at one step, paracetamol at another), focusing on mechanism differences, not “more of the same.”

6) NSAIDs: choose by profile, not by habit (dose, affinity, selectivity, risk)

NSAIDs vary by:

Mechanism via COX enzymes (COX-1 vs COX-2)
Selectivity (affects both efficacy and side effects)
Safety profile (notably GI, renal, and cardiovascular risks)

Practical conclusions stated:

For peripheral musculoskeletal pain, NSAIDs early are commonly reasonable starting options.
Opioids are reserved for more severe pain, and can sometimes be used with NSAIDs when appropriate (aiming for synergy rather than “competition”).

7) Safety “musts” highlighted for rational analgesic use

The lecture stressed screening to avoid misuse and reduce risk:

Gastric risk:
- History of gastritis/ulcer/gastric bleeding → be selective; avoid more gastrotoxic options.
Age risk:
- Avoid NSAIDs or use extreme caution in older adults (especially >65, also noted around 60–65) due to frailty and altered pharmacokinetics.
Polypharmacy:
- More medications increases interaction risks and reduces safe analgesic options.
Anticoagulated patients:
- NSAIDs can increase bleeding risk (antiplatelet effects).
Kidney/cardiovascular risk:
- NSAIDs may worsen renal perfusion and contribute to sodium retention → may worsen hypertension and cardiovascular outcomes.
Don’t treat analgesics “like candy”:
- Over-the-counter access does not mean low risk; routine OTC use without assessment is criticized.

8) Special caution points on specific drugs mentioned

Aspirin
- Dose-dependent effects:
  - Low dose: primarily antiplatelet benefit
  - Higher dose: additional analgesic/antipyretic effects
- GI bleeding risk remains a concern.
- Pediatrics: associated with Reye/RG syndrome → generally forbidden for children.
Paracetamol (acetaminophen)
- Good for fever and limited analgesia; weak anti-inflammatory effect.
- Risk of hepatotoxicity if exceeding max dose; lecture emphasized concern above 4 g/day and careful dosing.
Ketorolac
- Described as efficient but not very safe—requires strong attention to short-term use and dosing.
COX-2 inhibitors (“coxibs”)
- Discussed as having cardiovascular risks despite reduced GI effects.
- Used only for selected patients (e.g., GI vulnerability without cardiovascular contraindications).

Presenters / Sources

Presenter/Instructor: Referred to repeatedly as “professor”; the lecturer’s name was not clearly identified in the provided notes.
Named participant: Rachel Lira (appears as a student question/comment, not the main instructor)
Evidence source type: clinical trials and meta-analyses (no specific author names listed)